Abstract
PURPOSE OF REVIEW: Staphylococcus aureus is a significant human pathogen, causing a variety of infections, from skin and soft tissue infections to endocarditis, bone and joint infections and deep tissue abscesses. Mortality from S. aureus bacteraemia remains high, without major therapeutic advances in recent decades.
RECENT FINDINGS: In recent years, optimized dosing of antibiotics is increasingly being recognized as a cornerstone of management for severe infections including S. aureus bacteraemia. This comprehensive review details the pharmacokinetics/pharmacodynamics (PK/PD) targets for commonly used antistaphylococcal antibiotics and the doses predicted to achieve them in clinical practice. Recent advances in dosing of teicoplanin and use of cefazolin in CNS infections and findings from combination therapy studies are discussed. Drug exposure relationships related to toxicity are also detailed.
SUMMARY: This review details the different PK/PD targets for drugs used to treat S. aureus bacteraemia and how to apply them in various scenarios. The drug doses that achieve them, and the risks of toxicity are also provided.
| Original language | English |
|---|---|
| Pages (from-to) | 446-456 |
| Number of pages | 11 |
| Journal | Current Opinion in Critical Care |
| Volume | 29 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Oct 2023 |
Bibliographical note
Publisher Copyright:Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Fingerprint
Dive into the research topics of 'Optimal drug therapy for Staphylococcus aureus bacteraemia in adults'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver